BTG 1640  (Synonyms: ABIO-08/01)

BTG 1640 (ABIO-08/01) is a potent anxiolytic isoxazoline. BTG 1640 is a selective inhibitor of GABA- and glutamate-gated chloride channels^[1].

GABA- and glutamate-gated chloride channels^[1]

BTG 1640 (ABIO-08/01) displays an activity at a very low dosage after single intraperitoneal and single oral administration (gavage) in mouse and rat models of anxiety. Chronic administration resulted neither in tolerance development nor in withdrawal symptoms after abrupt discontinuation of treatment (data on file)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

245.32

C₁₅H₁₉NO₂

152538-59-5

CN1[C@H]([C@]2([H])[C@](CCCC2=O)([H])O1)CC3=CC=CC=C3

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Correll CU, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry. 2023 Feb;22(1):48-74.  [Content Brief]

  [2]. Saletu-Zyhlarz GM, et al. Double-blind, placebo-controlled, multiple-ascending-dose study on the pharmacodynamics of ABIO-08/01, a new CNS drug with potential anxiolytic activity. 1. EEG mapping, psychometric and tolerability findings. Neuropsychobiology. 2009;59(2):100-9.  [Content Brief]